STOCK TITAN
  1. Home
  2. News
  3. INCY

Incyte Corp Stock Price, News & Analysis

INCY Nasdaq

Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.

News for Incyte Genomics Inc (Nasdaq: INCY), operating as Incyte Corporation, centers on its activities as a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. Company releases describe a portfolio of first‑in‑class medicines and a pipeline of proprietary therapeutics, making INCY news particularly relevant for investors and healthcare observers following cancer and immune‑related drug development.

Recent headlines highlight late-stage clinical trial results and regulatory milestones. Incyte has reported positive topline data from the Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R‑CHOP as first‑line therapy for diffuse large B‑cell lymphoma, meeting primary and key secondary endpoints. Other news covers European Commission and Japanese approvals of Minjuvi in combination regimens for relapsed or refractory follicular lymphoma and DLBCL, underscoring the company’s role in B‑cell lymphoma treatment.

In immuno‑oncology, Incyte Biosciences Japan G.K. has announced approval of Zynyz (retifanlimab) with platinum‑based chemotherapy as first‑line treatment for advanced squamous cell carcinoma of the anal canal, following earlier U.S. approval in a similar setting. Additional coverage describes submissions to European regulators and the broader POD1UM clinical program evaluating retifanlimab across solid tumors.

News flow also features pipeline updates for INCA033989, a first‑in‑class mutCALR‑targeted monoclonal antibody for myeloproliferative neoplasms. Incyte has disclosed Breakthrough Therapy designation from the U.S. FDA for essential thrombocythemia with Type 1 CALR mutations, along with Phase 1 data in ET and myelofibrosis showing hematologic responses, spleen volume reductions, symptom improvements and safety findings.

Beyond R&D, Incyte issues releases on leadership changes, board transitions, inducement equity grants and participation in major healthcare investor conferences. For investors and analysts, the INCY news page provides a centralized view of clinical, regulatory, corporate governance and capital markets developments affecting the company.

News

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

Rhea-AI Summary

Incyte (NASDAQ:INCY) has announced a significant leadership transition with the appointment of Bill Meury as President and CEO, effective immediately. Meury succeeds Hervé Hoppenot, who is retiring after 11 years of leading the company. Under Hoppenot's tenure, Incyte grew from a single-product U.S. company to a global enterprise, increasing revenues from $355 million in 2013 to $4.2 billion currently.

Meury brings extensive industry experience as former CEO of Karuna and Anthos Therapeutics, and previously served as Chief Commercial Officer at Allergan, where he managed a $16 billion global business. Additionally, Julian Baker has been elected Chairman of the Board of Directors. Hoppenot will remain as a board member and advisor through 2025 to ensure a smooth transition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
management
-
News

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

Rhea-AI Summary
Incyte (INCY) announced that the FDA has extended the review period for ruxolitinib cream (Opzelura) for treating atopic dermatitis in children aged 2-11 years. The PDUFA date is pushed back by 3 months to September 19, 2025, allowing FDA to review additional CMC data for the 0.75% strength formulation. The sNDA submission was supported by Phase 3 TRuE-AD3 study results, which met its primary endpoint with significantly more patients achieving IGA-TS compared to vehicle control. The study also met its secondary endpoint with patients showing EASI75 improvement at Week 8. The safety profile remained consistent with previous data, showing only mild application site pain in 2.7% of treated patients, with no serious adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
fda approval
-
News

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Rhea-AI Summary
The FDA has approved Incyte's Monjuvi (tafasitamab-cxix) in combination with rituximab and lenalidomide for treating adult patients with relapsed or refractory follicular lymphoma (FL). This marks Monjuvi's second FDA approval, following its 2020 approval for DLBCL treatment. The Phase 3 inMIND trial demonstrated significant improvement in progression-free survival, with patients receiving Monjuvi achieving 22.4 months median PFS compared to 13.9 months in the control arm. The trial showed 27.5% of Monjuvi patients experienced events versus 47.6% in the control group. This approval represents the first FDA-approved CD19- and CD20-targeted immunotherapy combination for FL patients. The safety profile showed serious adverse reactions in 33% of patients, with respiratory tract infections and decreased neutrophils among the most common side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
fda approval
News

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Rhea-AI Summary
QIAGEN (QGEN) and Incyte (INCY) have announced a global collaboration to develop a novel diagnostic panel for myeloproliferative neoplasms (MPNs). The partnership focuses on creating a multimodal panel using next-generation sequencing technology to detect gene alterations in blood cancers, particularly targeting mutant calreticulin (mutCALR). The panel will support Incyte's drug portfolio, including INCA033989, and will be validated on Illumina's NextSeq 550Dx platform. QIAGEN will handle regulatory submissions and market access across the US, EU, and Asia-Pacific regions. The collaboration aims to improve treatment decisions for MPN patients, which represent about 40% of hematological malignancies, by enabling precise identification of genomic aberrations in biomarkers like CALR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Rhea-AI Summary
Incyte announced groundbreaking clinical data for INCA033989, their first-in-class mutCALR-targeted monoclonal antibody therapy for essential thrombocythemia (ET). The late-breaking data presented at EHA2025 showed remarkable efficacy, with 86% of patients receiving doses ≥400mg achieving complete or partial hematologic response, and 82% reaching complete response. The drug demonstrated disease-modifying potential by selectively targeting and reducing mutCALR cells while promoting healthy blood cell production. In the study of 49 patients, 89% showed reduced mutCALR variant allele frequency. Safety profile was favorable with no dose-limiting toxicities, and 98% of patients maintained treatment. Most common side effects were mild, including fatigue (26.5%) and upper respiratory infections (20.4%). The company plans to initiate Phase 3 trials by early 2026 following regulatory discussions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

Rhea-AI Summary
Incyte (INCY) announced the publication of Phase 3 POD1UM-303/InterAACT 2 trial results for Zynyz® (retifanlimab-dlwr) in The Lancet. The trial demonstrated significant benefits when combining retifanlimab with carboplatin-paclitaxel chemotherapy for treating advanced squamous cell carcinoma of the anal canal (SCAC). The study showed a 37% reduction in progression/death risk, with median progression-free survival of 9.3 months versus 7.4 months in the placebo group. Overall response rate improved to 55.8% with retifanlimab versus 44.2% with placebo. In May 2025, the FDA approved Zynyz® both in combination with chemotherapy for first-line treatment and as a single agent for advanced SCAC patients. Applications are under review by EMA and PMDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
clinical trial
News

Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions

Rhea-AI Summary
Specialised Therapeutics (ST) has expanded its partnership with Incyte to distribute two additional oncology therapies - axatilimab (Niktimvo) and retifanlimab (Zynyz) - in Australia, New Zealand, and Singapore. These medicines join the existing portfolio of Minjuvi and Pemazyre. Axatilimab, approved by FDA in August 2024, treats chronic graft-versus-host disease in patients who've had at least two prior treatments. Retifanlimab is approved for treating squamous cell carcinoma of the anal canal and Merkel cell carcinoma, with Australia having the highest MCC incidence globally. Under the agreement, Incyte will handle development and manufacturing, while ST will manage regulatory affairs, distribution, and local marketing. ST plans to submit both drugs for regulatory and reimbursement approval in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
partnership
-
News

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Incyte (INCY) has granted restricted stock unit awards (RSUs) totaling 16,550 shares to 19 new employees under its 2024 Inducement Stock Incentive Plan. The grants, effective June 2, 2025, were approved by the company's compensation committee as an inducement for new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting annually, contingent on continued employment with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
News

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

Rhea-AI Summary
Incyte (INCY) announced multiple presentations at the 2025 European Hematology Association Congress in Milan, featuring late-breaking data for INCA033989, their novel mutCALR-directed monoclonal antibody for essential thrombocythemia (ET). The presentations include data from their hematology/oncology portfolio, with a key focus on INCA033989's potential as a disease-modifying treatment for myeloproliferative neoplasms. The congress will feature presentations on various programs including INCA035784, ruxolitinib, tafasitamab, axatilimab, INCB057643, and ponatinib. Incyte will host an analyst and investor event on June 15, 2025, from 6:00-7:30 a.m. EDT to discuss the mutCALR data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
none
News

Incyte to Present at Upcoming Investor Conference

Rhea-AI Summary

Incyte (Nasdaq: INCY) has announced its upcoming participation at the Goldman Sachs Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025 at 11:20 am ET. Investors and interested parties can access the live webcast through Investor.Incyte.com, with the replay remaining available for 30 days following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
conferences

FAQ

What is the current stock price of Incyte (INCY)?

The current stock price of Incyte (INCY) is $102.6 as of February 4, 2026.

What is the market cap of Incyte (INCY)?

The market cap of Incyte (INCY) is approximately 19.8B.
Stock INCY logo
Incyte Corp

Nasdaq:INCY

INCY Rankings

#617 Ranked by Market Cap
N/A Ranked by Dividends

INCY Stock Data

19.81B
192.29M
2.03%
103.47%
3.85%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON

INCY RSS Feed